Cardiff Oncology Details Positive Phase 2 Onvansertib Data, Aligns with FDA on Phase 3 Trial Design
CRDF is trading near its 52-week low of $1.4 (7.1% above the low) on elevated volume (3.0× avg).
Summary
Cardiff Oncology disclosed detailed positive Phase 2 data for onvansertib, showing superior efficacy and a favorable safety profile, and announced alignment with the FDA on a Phase 3 registrational trial design.
Key Events · Product Development and Regulatory · CRDF
-
Positive Phase 2 CRDF-004 Results
Onvansertib combined with FOLFIRI/bevacizumab demonstrated a 72% Objective Response Rate (ORR), a 30% improvement over standard of care, and median Progression-Free Survival (PFS) was not reached versus 12.2 months in the control arm for first-line RAS-mutated mCRC.
-
FDA Alignment on Phase 3 Design
The company completed a successful End-of-Phase 2 meeting with the FDA, agreeing on a pivotal Phase 3 registrational trial (CRDF-005) designed to support both accelerated approval (based on ORR) and full approval (based on PFS).
-
Favorable Safety Profile
Onvansertib showed no unexpected, overlapping, or new toxicities when added to FOLFIRI/bevacizumab or FOLFOX/bevacizumab, with side effects consistent with background therapy.
-
Addresses Unmet Medical Need
The drug targets a large, underserved population in first-line RAS-mutated mCRC, an area with limited innovation over the past two decades.
Analysis · CRDF · Life Sciences
This filing provides detailed positive Phase 2 clinical trial results for Cardiff Oncology's lead drug, onvansertib, in first-line RAS-mutated metastatic colorectal cancer. Crucially, it confirms a successful End-of-Phase 2 meeting with the FDA, establishing a clear registrational path for a pivotal Phase 3 trial. This news is highly significant, especially following the recent termination of the onvansertib license agreement and a 'going concern' warning, as it provides a strong positive signal for the drug's future and the company's viability.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.2% of the 386 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.2M. The 52-week trading range was $1.40 to $4.56. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.